FDA authorizes emergency use of Eli Lilly coronavirus antibody treatment

The US Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly's combination antibody therapy to fight COVID-19, the US drugmaker said on Tuesday.
Eli Lilly's combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%, data from a late-stage trial showed in January.
"This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization," the company said in a statement. 
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy